连续性肾脏替代治疗中局部枸橼酸抗凝的应用
Application of Local Citrate Anticoagulation in Continuous Renal Replacement Therapy
DOI: 10.12677/ACM.2023.13112458, PDF,   
作者: 吕博贻：青海大学临床医学院，青海 西宁；张 斌*：青海省人民医院急诊ICU，青海 西宁
关键词: 急性肾损伤；连续性肾脏替代治疗；局部柠檬酸盐抗凝；Acutekidney Injury； Continuous Renal Replacement Therapy； Regional Citrate Anticoagulation
摘要: 连续性肾脏替代治疗(CRRT)中有效透析剂量的输送取决于体外回路的充分抗凝。在大多数患者中，使用全身肝素抗凝或局部枸橼酸盐抗凝(RCA)。本综述将概述RCA的基础和原理，并总结两种技术的安全性和有效性数据。RCA的基本原理是通过输注枸橼酸盐来降低体外回路中的离子钙水平，通过这种方式，实现了仅限于体外回路的有效抗凝。在不同的研究中，对肝素抗凝与RCA进行了比较。RCA可明显地提高过滤器的使用寿命，降低出血并发症，并能很好地控制尿毒症及酸碱平衡，并且对大部分肝脏损伤患者也都是安全的。在CRRT中，RCA是一种安全、有效的抗凝治疗方法，其抗凝效果优于肝素抗凝，并可降低不良反应。在ICU患者中，大多数CRRT治疗均可推荐RCA抗凝模式。
Abstract: The delivery of an effective dialysis dose in continuous renal replacement therapy (CRRT) depends on adequate anticoagulation of the extracorporeal circuit. In most patients, either systemic heparin anticoagulation (SHA) or regional citrate anticoagulation (RCA) is used. This review will outline the basics and rationale of RCA and summarize data on safety and efficacy of both techniques. The basic principle of RCA is to reduce the level of ionized calcium in the extracorporeal circuit via infusion of citrate. This way, effective anticoagulation restricted to the extracorporeal circuit is achieved. SHA and RCA were compared in a variety of studies. RCA significantly prolonged filter lifetime, reduced bleeding complications and provided excellent control of uremia and acid-base status. RCA was also safe in the majority of patients with impaired liver function.RCA per se is safe and effective for anti-coagulation of CRRT. Compared to SHA, efficacy of anticoagulation is improved and adverse effects are reduced. RCA can be recommended as the anticoagulation mode of choice for CRRT in most ICU patients.
文章引用：吕博贻, 张斌. 连续性肾脏替代治疗中局部枸橼酸抗凝的应用[J]. 临床医学进展, 2023, 13(11): 17542-17548. https://doi.org/10.12677/ACM.2023.13112458

参考文献

[1] 季大玺, 龚德华. 应重视连续性肾脏替代治疗在危重病中的应用[J]. 中国血液净化, 2007, 6(11): 581-583.
[2] MacEwen, C., Watkinson, P. and Winearls, C. (2015) Circuit Life versus Bleeding Risk: The Impact of Achieved Activated Partial Thromboplastin Time versus Achieved Filtration Fraction. Therapeutic Apheresis and Dialy-sis, 19, 259-266. [Google Scholar] [CrossRef] [PubMed]
[3] Brandenburger, T., Dimski, T., Slowinski, T., et al. (2017) Renal Replacement Therapy and Anticoagulation. Best Practice & Research Clinical Anaesthesiology, 3, 387-401. [Google Scholar] [CrossRef] [PubMed]
[4] Monchi, M. (2017) Citrate Pathophysiology and Metabolism. Transfusion and Apheresis Science, 56, 28-30. [Google Scholar] [CrossRef] [PubMed]
[5] Morita, Y., Johnson, R.W., Dorn, R.E., et al. (1961) Regional Anticoagulation during Hemodialysis Using Citrate. The American Journal of the Medical Sciences, 1961, 32-43.
[6] Mehta, R.L., McDonald, B.R., Aguilar, M.M., et al. (1990) Regional Citrate Anticoagulation for Continu-ous Arteriovenous Hemodialysis in Critically Ill Patients. Kidney International, 5, 976-981. [Google Scholar] [CrossRef] [PubMed]
[7] 严海燕, 黄雪敏, 李大亮, 等. 局部枸橼酸抗凝在重症急性肾损伤患者连续性肾脏替代治疗中的应用分析[J]. 实用中西医结合临床, 2022, 22(17): 31-33, 37. [Google Scholar] [CrossRef] 
[8] Morgera, S., Schneider, M., Slowinski, T., et al. (2009) A Safe Citrate Anticoagulation Protocol with Variable Treatment Efficacy and Excellent Control of the Acid-Base Status. Critical Care Medicine, 27, 2018-2024. [Google Scholar] [CrossRef] 
[9] Hetzel, G.R., Taskaya, G., Sucker, C., et al. (2006) Citrate Plasma Levels in Patients under Regional Anticoagulation in Continuous Venovenous Hemofiltration. American Journal of Kidney Diseases, 48, 806-811. [Google Scholar] [CrossRef] [PubMed]
[10] Durão, M.S., Monte, J.C., Batista, M.C., et al. (2008) The Use of Regional Citrate Anticoagulation for Continuous Venovenous Hemodiafiltration in Acute Kidney Injury. Critical Care Medicine, 36, 3024-3029. [Google Scholar] [CrossRef] 
[11] Bai, M., Zhou, M., He, L., et al. (2015) Citrate versus Hep-arin Anticoagulation for Continuous Renal Replacement Therapy: An Updated Meta-Analysis of RCTs. Intensive Care Medicine, 41, 2098-2110. [Google Scholar] [CrossRef] [PubMed]
[12] Slowinski, T., Morgera, S., Joannidis, M., et al. (2015) Safety and Efficacy of Regional Citrate Anticoagulation in Continuous Venovenous Hemodialysis in the Presence of Liver Failure: tHe Liver Citrate Anticoagulation Threshold (L-CAT) Observational Study. Critical Care, 19, Article No. 349. [Google Scholar] [CrossRef] [PubMed]
[13] Khwaja, A. (2012) KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice, 120, c179-c184. [Google Scholar] [CrossRef] [PubMed]
[14] 吉彪. 枸橼酸体外抗凝技术在ICU急性肾损伤患者肾替代治疗中的临床应用研究[D]: [硕士学位论文]. 乌鲁木齐: 新疆医科大学, 2021.[CrossRef] 
[15] Monchi, M., Berghmans, D., Ledoux, D., et al. (2004) Citrate vs. Heparin for Anticoagulation in Continuous Venovenous Hemofiltration: A Prospective Randomized Study. Intensive Care Medicine, 30, 260-265. [Google Scholar] [CrossRef] [PubMed]
[16] Oudemans-van Straaten, H.M. (2010) Citrate Anticoagulation for Continuous Renal Replacement Therapy in the Critically Ill. Blood Purification, 29, 191-196. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, C., Mao, Z., Kang, H., et al. (2016) Regional Citrate versus Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients: A Meta-Analysis with Trial Se-quential Analysis of Randomized Controlled Trials. Critical Care, 20, Article No. 144. [Google Scholar] [CrossRef] [PubMed]
[18] Kalb, R., Kram, R., Morgera, S., et al. (2013) Regional Citrate Anticoagulation for High Volume Continuous Venovenous Hemodialysis in Surgical Patients with High Bleeding Risk. Therapeutic Apheresis and Dialysis, 17, 202-212. [Google Scholar] [CrossRef] [PubMed]
[19] Park, J.S., Kim, G.H., Kang, C.M., et al. (2011) Regional Anticoagulation with Citrate Is Superior to Systemic Anticoagulation with Heparin in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. The Korean Journal of Internal Medicine, 26, 68-75. [Google Scholar] [CrossRef] [PubMed]
[20] Morabito, S., Pistolesi, V., Tritapepe, L., et al. (2012) Regional Cit-rate Anticoagulation in Cardiac Surgery Patients at High Risk of Bleeding: A Continuous Veno-Venous Hemofiltration Protocol with a Low Concentration Citrate Solution. Critical Care, 16, Article No. R111. [Google Scholar] [CrossRef] [PubMed]
[21] Shum, H.P., Chan, K.C. and Yan, W.W. (2012) Regional Citrate Anticoagu-lation in Predilution Continuous Venovenous Hemofiltration Using Prismocitrate 10/2 Solution. Therapeutic Apheresis and Dialysis, 16, 81-86. [Google Scholar] [CrossRef] [PubMed]
[22] Jacobs, R., Honore, P.M., Hendrickx, I. and Spapen, H.D. (2016) Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: All Citrates Are Not Created Equal! Blood Purification, 42, 219-220. [Google Scholar] [CrossRef] [PubMed]
[23] Zhang, Z. and Hongying, N. (2012) Efficacy and Safety of Regional Cit-rate Anticoagulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy. Intensive Care Medi-cine, 38, 20-28. [Google Scholar] [CrossRef] [PubMed]
[24] Klingele, M., Seiler, S., Poppleton, A., et al. (2014) The Gap be-tween Calculated and Actual Calcium Substitution during Citrate Anticoagulation in an Immobilised Patient on Renal Re-placement Therapy Reflects the Extent of Bone Loss—A Case Report. BMC Nephrology, 15, Article No. 163. [Google Scholar] [CrossRef] [PubMed]
[25] Raimundo, M., Crichton, S., Lei, K., et al. (2013) Maintaining Normal Levels of Ionized Calcium during Citrate-Based Renal Replacement Therapy Is Associated with Stable Parathy-roid Hormone Levels. Nephron Clinical Practice, 124, 124-131. [Google Scholar] [CrossRef] [PubMed]
[26] Khadzhynov, D., Dahlinger, A., Schelter, C., et al. (2017) Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replace-ment Therapy with Regional Citrate Anticoagulation. Critical Care Medicine, 45, e941-e946. [Google Scholar] [CrossRef] 
[27] Schultheiß, C., Saugel, B., Phillip, V., et al. (2012) Con-tinuous Venovenous Hemodialysis with Regional Citrate Anticoagulation in Patients with Liver Failure: A Prospective Observational Study. Critical Care, 16, Article No. R162. [Google Scholar] [CrossRef] [PubMed]
[28] Kramer, L., Bauer, E., Joukhadar, C., et al. (2003) Citrate Pharmacokinetics and Metabolism in Cirrhotic and Noncirrhotic Critically Ill Patients. Critical Care Medicine, 31, 2450-2455. [Google Scholar] [CrossRef] 
[29] 刘京鹤, 杜春静, 刘景院, 等. 肝衰竭合并急性肾损伤患者接受局部枸橼酸抗凝的持续肾脏替代治疗中发生代谢不良反应的危险因素[J]. 中国肝脏病杂志(电子版), 2022, 14(3): 45-52.
[30] Meier-Kriesche, H.U.,Gitomer, J., Finkel, K., et al. (2001) Increased Total to Ionized Cal-cium Ratio during Continuous Venovenous Hemodialysis with Regional Citrate Anticoagulation. Critical Care Medicine, 29, 748-752. [Google Scholar] [CrossRef] [PubMed]
[31] Saner, F.H., Treckmann, J.W., Geis, A., et al. (2012) Efficacy and Safety of Regional Citrate Anticoagulation in Liver Transplant Patients Requiring Post-Operative Renal Re-placement Therapy. Nephrology Dialysis Transplantation, 29, 1651-1657. [Google Scholar] [CrossRef] [PubMed]

为你推荐